Everolimus-eluting stents in interventional cardiology.

Major adverse cardiac events, including death, myocardial infarction, and ischemic target lesion revascularization, all occurred less frequently with the everolimus-eluting stent, but the differences did not reach statistical significance (2% everolimus-eluting stent versus 5.3% sirolimus-eluting stent, P = 0.218 for the combined endpoint; and 0.7% everolimus-eluting stent versus 2.6% sirolimus-eluting stent, P = 0.32 for target lesion revascularization).

also in 111,027 other papers